Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
20多个州的总检察长对暂停堕胎药物批准敲响警钟：未来有 “毁灭性风险”
- In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating risks to millions of people," including those in states where abortion remains legal.
- The attorneys general, in their filing, called on the U.S. 5th Circuit Court of Appeals to keep mifepristone on the market.
- Last week Friday, a U.S. judge suspended the FDA's approval of mifepristone, an abortion pill to terminate a pregnancy through ten weeks gestation.
- But he put his decision on hold for one week to give the Biden administration time to appeal.
- Also Read - Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension.
- Kacsmaryk's ruling will take effect at 12 a.m. CT on Saturday if the 5th Circuit does not halt it.
- Citing the filing, CNBC reported that attorneys general and the District of Columbia condemned Kacsmaryk's ruling as "legally erroneous" and warned it would undermine the FDA's approval process.
- The attorneys general argued that Kacsmaryk's order would "eviscerate the sovereign decisions" made by the states to protect access to abortion when last year, the Supreme Court's decision overturned Roe v. Wade, which said there was a federal constitutional right to abortion.
- Kacsmaryk's decision does not affect the availability of misoprostol, which the World Health Organization recommends as a standalone abortion drug.
- States such as California are stockpiling misoprostol if Kacsmaryk's decision goes into effect.
- Photo via Wikimedia Commons
- 据报道，在一份新的法庭文件中，美国23个州的民主党总检察长警告说，联邦法官暂停美国食品药品管理局对米非司酮的批准的决定 “对数百万人构成了毁灭性风险”，其中包括堕胎仍然合法的州。
- 总检察长在文件中呼吁美国第五巡回上诉法院将米非司酮保留在市场上。
- 上周五，一名美国法官暂停了美国食品药品管理局对米非司酮的批准，米非司酮是一种在妊娠十周之前终止妊娠的堕胎药。
- 但他将决定搁置一周，以便让拜登政府有时间提出上诉。
- 另请阅读- 制药商捍卫生殖权利：谴责暂停批准堕胎药的300家中有辉瑞和Biogen。
- 如果第五巡回法院不停止裁决，Kacsmaryk的裁决将在美国东部时间周六上午12点生效。
- CNBC援引该文件报道说，总检察长和哥伦比亚特区谴责Kacsmaryk的裁决是 “法律错误的”，并警告说这将破坏FDA的批准程序。
- 总检察长辩称，卡斯马雷克的命令将 “削弱各州为保护堕胎机会而做出的主权决定”，而去年，最高法院的裁决推翻了罗伊诉韦德案，该案称联邦有堕胎的宪法权利。
- Kacsmaryk的决定并不影响米索前列醇的供应，世界卫生组织建议将米索前列醇作为一种独立的堕胎药物。
- 如果卡斯马雷克的决定生效，加利福尼亚州等州将储存米索前列醇。
- 照片来自维基共享资源
资讯热榜
更新时间